Search

High Nasopharyngeal Carriage of Non-Vaccine Serotypes in Western Australian Aboriginal People Following 10 Years of Pneumococcal Conjugate Vaccination

Invasive pneumococcal disease (IPD) continues to occur at high rates among Australian Aboriginal people.

Djaalinj Waakinj (listening talking): Rationale, cultural governance, methods, population characteristics–an urban Aboriginal birth cohort study of otitis media

The majority of Australian Aboriginal and Torres Strait Islander (hereafter referred to as “Aboriginal”) people live in urban centres. Otitis media (OM) occurs at a younger age, prevalence is higher and hearing loss and other serious complications are more common in Aboriginal than non-Aboriginal children. Despite this, data on the burden of OM and hearing loss in urban Aboriginal children are limited.

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.

Limited impact of neonatal or early infant schedules of 7-valent pneumococcal conjugate vaccination

Early 7vPCV schedules have limited impact on pneumococcal vaccine type carriage in PNG

Rhinovirus species and clinical features in children hospitalised with pneumonia from Mozambique

The prevalence of human rhinovirus (RV) species in children hospitalised with pneumonia in Manhiça, Mozambique

A systematic review of the evidence that swimming pools improve health and wellbeing in remote Aboriginal communities in Australia

The benefits that swimming pools may bring to to ear and eye health in remote Aboriginal communities remains unresolved

BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial)

BCG vaccination modulates immune responses to unrelated pathogens. This off-target effect could reduce the impact of emerging pathogens. As a readily available, inexpensive intervention that has a well-established safety profile, BCG is a good candidate for protecting healthcare workers (HCWs) and other vulnerable groups against COVID-19.

Respiratory viruses in young South African children with acute lower respiratory infections and interactions with HIV

RV-A and RV-C are endemic in South African children and HIV infection may be protective against RSV and bronchiolitis.

Safety and Immunogenicity of Neonatal Pneumococcal Conjugate Vaccination in Papua New Guinean Children: A Randomised Controlled Trial

We conducted an open randomized controlled trial in Papua New Guinea to compare safety, immunogenicity and priming for memory of 7-valent PCV (PCV7) given in...

Reduction in disparity for pneumonia hospitalisations between Australian indigenous and non-Indigenous children

In the 1990s pneumonia hospitalisation rates in Western Australia (WA) were 13 times higher in Indigenous children than in non-Indigenous children...